{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:40:05Z","timestamp":1783978805946,"version":"3.55.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Orthop Relat Res"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Aspirin is established as an effective prophylaxis for venous thromboembolism (VTE) after THA; however, there is no consensus as to whether low- or regular-dose aspirin is more effective at preventing VTE.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Questions\/purposes<\/jats:title>\n            <jats:p>(1) Is there a difference in the incidence of symptomatic VTE within 90 days of elective THA using low-dose aspirin compared with regular-dose aspirin? (2) Is there a difference in the risk of significant bleeding (gastrointestinal and wound bleeding) and mortality between low- and standard-dose aspirin within 90 days after surgery?<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We retrospectively evaluated 7488 patients in our database who underwent THA between September 2012 and December 2016. A total of 3936 (53%) patients received aspirin alone for VTE prophylaxis after THA. During the study period, aspirin was prescribed as a monotherapy for VTE prophylaxis after surgery in low-risk patients (no history of VTE, recent orthopaedic surgery, hypercoagulable state, history of cardiac arrhythmia requiring anticoagulation, or receiving anticoagulation for any other medical conditions before surgery). Patients were excluded if aspirin use was contraindicated because of peptic ulcer disease, intolerance, or other reasons. Patients received aspirin twice daily (BID) for 4 to 6 weeks after surgery and were grouped into two cohorts: a low-dose (81 mg BID) aspirin group (n = 1033) and a standard-dose (325 mg BID) aspirin group (n = 2903). The primary endpoint was symptomatic VTE (deep vein thrombosis [DVT] and pulmonary embolism [PE]). Secondary endpoints included significant bleeding (gastrointestinal [GI] and wound) and mortality. Exploratory univariate analyses were used to compare confounders between the study groups. Multivariate regression was used to control for confounding variables (including age, sex, body mass index, comorbidities, and surgeon) as we compared the study groups with respect to the proportion of patients who developed symptomatic VTE, bleeding (GI or wound), and mortality within 90 days of surgery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The 90-day incidence of symptomatic VTE was 1.0% in the 325-mg group and 0.6% in the 81-mg group (p = 0.35). Symptomatic DVT incidence was 0.8% in the 325-mg group and 0.5% in the 81-mg group (p = 0.49), and the incidence of symptomatic PE was 0.3% in the 325-mg group and 0.2% in the 81-mg group (p = 0.45). Furthermore, bleeding was observed in 0.8% of the 325-mg group and 0.5% of the 81-mg group (p = 0.75), and 90-day mortality was not different (0.1%) between the groups (p = 0.75). After accounting for confounders, regression analyses showed no difference between aspirin doses and the 90-day incidence of symptomatic VTE (odds ratio [OR], 0.90; 95% confidence interval [CI], 0.29-2.85; p = 0.85) or symptomatic DVT (OR, 0.96; 95% CI, 0.26-3.59; p = 0.95).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>We found no difference in the incidence of symptomatic VTE after THA with low-dose compared with standard-dose aspirin. In the absence of compelling evidence to the contrary, low-dose aspirin appears to be a reasonable option for VTE prophylaxis in otherwise healthy patients undergoing elective THA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Level of Evidence<\/jats:title>\n            <jats:p>Level III, therapeutic study.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/corr.0000000000000613","type":"journal-article","created":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T08:49:58Z","timestamp":1547887798000},"page":"396-402","source":"Crossref","is-referenced-by-count":38,"title":["No Difference Between Low- and Regular-dose Aspirin for Venous Thromboembolism Prophylaxis After THA"],"prefix":"10.1097","volume":"477","author":[{"given":"Mhamad","family":"Faour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas S.","family":"Piuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Brigati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison K.","family":"Klika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Mont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael K.","family":"Barsoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Higuera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,1,16]]},"reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.arth.2016.04.004","article-title":"Aspirin as thromboprophylaxis in hip and knee arthroplasty: a systematic review and meta-analysis","volume":"31","author":"An","year":"2016","journal-title":"J Arthroplasty"},{"key":"R2-20230814","first-page":"800","article-title":"Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial","volume":"4","author":"Anderson","year":"2016","journal-title":"Ann Intern Med"},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.arth.2009.06.021","article-title":"Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients?","volume":"25","author":"Bozic","year":"2010","journal-title":"J Arthroplasty"},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/cpt.874","article-title":"Lack of bioequivalence among low-dose, enteric-coated aspirin preparations","volume":"103","author":"Cox","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/01.blo.0000201157.29325.f0","article-title":"Venous thromboembolism is rare with a multimodal prophylaxis protocol after total hip arthroplasty","volume":"443","author":"DeLaValle","year":"2006","journal-title":"Clin Orthop Relat Res"},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/j.arth.2018.03.001","article-title":"Low-dose aspirin is safe and effective for venous thromboembolism prophylaxis following total knee arthroplasty","volume":"33","author":"Faour","year":"2018","journal-title":"J Arthroplasty"},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1016\/j.arth.2017.01.009","article-title":"A Comparison of two dosing regimens of ASA following total hip and knee arthroplasties","volume":"32","author":"Feldstein","year":"2017","journal-title":"J Arthroplasty"},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/FJC.0000000000000387","article-title":"Aspirin use in secondary cardiovascular protection and the development of aspirin-associated erosions and ulcers","volume":"68","author":"Goldstein","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bcpt.12362","article-title":"Enteric coating can lead to reduced antiplatelet effect of low-dose acetylsalicylic acid","volume":"116","author":"Haastrup","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.arth.2016.02.074","article-title":"Aspirin is as effective as and safer than warfarin for patients at higher risk of venous thromboembolism undergoing total joint arthroplasty","volume":"31","author":"Huang","year":"2016","journal-title":"J Arthroplasty"},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2106\/00004623-197658070-00005","article-title":"A clinical evaluation of aspirin prophylaxis of thromboembolic disease after total hip arthroplasty","volume":"58","author":"Jennings","year":"1976","journal-title":"J Bone Joint Surg Am"},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.2106\/JBJS.I.00511","article-title":"American academy of orthopaedic surgeons clinical practice guideline on symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty","volume":"91","author":"Johanson","year":"2009","journal-title":"J Bone Joint Surg Am"},{"key":"R17-20230814","first-page":"128","article-title":"Prevention of thromboembolic disease after non-cemented hip arthroplasty. A multimodal approach","volume":"68","author":"Leali","year":"2002","journal-title":"Acta Orthop Belg"},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00003086-199603000-00031","article-title":"Aspirin and warfarin for thromboembolic disease after total joint arthroplasty","volume":"324","author":"Lotke","year":"1996","journal-title":"Clin Orthop Relat Res"},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0883-5403(06)80238-X","article-title":"Aspirin prophylaxis and surveillance of pulmonary embolism and deep vein thrombosis in total hip arthroplasty","volume":"5","author":"McCardel","year":"1990","journal-title":"J Arthroplasty"},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/01.prs.0000475790.54231.28","article-title":"Benefits and risks of prophylaxis for deep venous thrombosis and pulmonary embolus in plastic surgery: a systematic review and meta-analysis of controlled trials and consensus conference","volume":"137","author":"Pannucci","year":"2016","journal-title":"Plast Reconstr Surg"},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2106\/JBJS.16.00147","article-title":"Low-dose aspirin is effective chemoprophylaxis against clinically important venous thromboembolism following total joint arthroplasty","volume":"99","author":"Parvizi","year":"2017","journal-title":"J Bone Joint Surg Am"},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(00)02110-3","article-title":"Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"R23-20230814","first-page":"397","article-title":"Causes and rates of unplanned readmissions after elective primary total joint arthroplasty: a systematic review and meta-analysis","volume":"44","author":"Ramkumar","year":"2015","journal-title":"Am J Orthop (Belle Mead NJ)"},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s11999-013-3135-z","article-title":"Aspirin: an alternative for pulmonary embolism prophylaxis after arthroplasty?","volume":"472","author":"Raphael","year":"2014","journal-title":"Clin Orthop Relat Res"},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-2125.1993.tb05689.x","article-title":"The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials","volume":"35","author":"Roderick","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2106\/00004623-197658070-00004","article-title":"Thromboembolism following total hip-replacement arthroplasty. The efficicy of dextran-aspirin and dextran-warfarin in prophylaxis","volume":"58","author":"Salvati","year":"1976","journal-title":"J Bone Joint Surg Am"},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM197106102842303","article-title":"Reduction in venous thromboembolism by agents affecting platelet function","volume":"284","author":"Salzman","year":"1971","journal-title":"N Engl J Med"},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s11999-007-0092-4","article-title":"Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty","volume":"466","author":"Sharrock","year":"2008","journal-title":"Clin Orthop Relat Res"},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/S0140-6736(99)05388-X","article-title":"Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators","volume":"353","author":"Taylor","year":"1999","journal-title":"Lancet"},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00003086-198910000-00026","article-title":"Prevention of thromboembolism following elective hip surgery. The value of regional anesthesia and graded compression stockings","volume":"247","author":"Wille-J\u00f8rgensen","year":"1989","journal-title":"Clin Orthop Relat Res"}],"container-title":["Clinical Orthopaedics &amp; Related Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003086-201902000-00027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T05:26:23Z","timestamp":1691990783000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003086-201902000-00027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,16]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/corr.0000000000000613","relation":{},"ISSN":["0009-921X"],"issn-type":[{"value":"0009-921X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,16]]}}}